Dawnrays Pharmaceutical (Holdings) Limited

Announcements & Notices       

2021-December-22	UPDATE ON JOINT VENTURE COMPANY-EARLY COMPLETION OF PATIENT ENROLLMENT OF EBRONUCIMAB (PCSK9 MONOCLONAL ANTIBODY, AK102) IN A PHASE III CLINICAL TRIAL FOR PRIMARY HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA IN THE PRC (in PDF)
2021-September-23	BUSINESS UPDATE-PRODUCT COOPERATION AGREEMENTS (in PDF)
2021-September-9	BUSINESS UPDATE- INITIATION OF PHASE III CLINICAL TRIAL FOR PRIMARY HYPERCHOLESTEROLEMIA AND MIXED HYPERLIPIDEMIA OF AK102 AND INCREASE IN CAPITAL CONTRIBUTION IN JOINT VENTURE (in PDF)
2021-August-27	Interim Dividend for the year ending 31 December 2021 and Closure of Register of Members (in PDF)
2021-August-27	ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021 (in PDF)
2021-August-16	DATE OF BOARD MEETING (in PDF)
2021-July-30	BUSINESS UPDATE-DISPOSAL OF INTEREST IN A SUBSIDIARY (in PDF)
2021-May-28	POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 28 MAY 2021 (in PDF)
2021-April-19	NOTICE OF ANNUAL GENERAL MEETING (in PDF)
2021-March-31	GRANT OF OPTIONS (in PDF)
2021-March-26	ANNOUNCEMENT OF THE ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020 (in PDF)
2021-March-15	DATE OF BOARD MEETING (in PDF)
2021-February-2	DISCLOSEABLE TRANSACTION - PROVISION OF FINANCIAL ASSISTANCE (in PDF)
2024	2024 Announcements & Notices
2023	2023 Announcements & Notices
2022	2022 Announcements & Notices
2020	2020 Announcements & Notices
2019	2019 Announcements & Notices
2018	2018 Announcements & Notices
2017	2017 Announcements & Notices